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Abstract
The DNA sequences were determined for the lipoprotein lipase
(LPL) gene from five unrelated Japanese patients with familial
LPL deficiency. The results demonstrated that all five patients
are homozygotes for distinct point mutations dispersed
throughout the LPL gene. Patient 1 has a G-to-A transition at
the first nucleotide of intron 2, which abolishes normal splicing.
Patient 2 has a nonsense mutation in exon 3 (Tyr" -> Stop) and
patient 3 in exon 8 (Trp"2 -- Stop). The latter mutation em-
phasizes the importance of the carboxy-terminal portion of the
enzyme in the expression ofLPL activity. Missense mutations
were identified in patient 4 (Asp2'- Glu) and patient 5 (Arg'3
His) in the strictly conserved amino acids. Expression study
of both mutant genes in COS-1 cells produced inactive en-
zymes, establishing the functional significance of the two mis-
sense mutations. In these patients, postheparin plasma LPL
mass was either virtually absent (patients 1 and 2) or signifi-
cantly decreased (patients 3-5). To detect these mutations
more easily, we developed a rapid diagnostic test for each muta-
tion. We also determined the DNA haplotypes for patients and
confirmed the occurrence of multiple mutations on the chromo-
somes with an identical haplotype. These results demonstrate
that familial LPL deficiency is a heterogeneous genetic disease
caused by a wide variety of gene mutations. (J. Clin. Invest.
1991. 88:1856-1864.) Key words: chylomicron - point mutation
* genetic disease * mutagenesis - haplotype
Introduction
Lipoprotein lipase (LPL)' plays a central role in triglyceride
metabolism through catabolism oftriglyceride-rich lipoprotein
particles such as chylomicron and VLDL. LPL is a glycopro-
tein synthesized in most extrahepatic tissues and is anchored to
the luminal surface ofthe capillary endothelium by membrane
bound heparan sulfate. The action of LPL is necessary for the
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supply of free fatty acids to tissues for oxidation or storage and
is also an important determinant for the interconversions
among lipoprotein particles (1).
A patient with a familial form ofchylomicronemia was first
described in 1932 (2) and LPL deficiency was noted as a cause
of familial chylomicronemia in 1960 (3). Familial LPL defi-
ciency is inherited as an autosomal recessive trait and its occur-
rence has been estimated to be approximately one in a million.
The disease usually presents in infancy or childhood with epi-
sodic abdominal pain and abnormal appearances of lipemic
plasma. The patients have severe chylomicronemia due to a
defective hydrolysis of chylomicrons, a marked elevation of
fasting serum triglyceride concentrations, and a drastically re-
duced postheparin plasma LPL activity. Other clinical features
of this disease include eruptive xanthoma, lipemia retinalis,
hepatosplenomegaly due to the accumulation of chylomicron
fat, and recurrent attacks of pancreatitis which are often fatal
(4). The heterogeneity of this disease has been suggested by the
various degrees of lipolytic activity which were detected in pa-
tients upon administration of exogenous triglyceride substrate
(5) and heparin infusion (6). Recent experiments using a mono-
clonal antibody against LPL disclosed the classification of pa-
tients into three subgroups with distinct biochemical character-
istics (7).
Both the molecular cloning of LPL cDNAs (8, 9) and the
elucidation of the human LPL gene structure (10-12) greatly
facilitated genomic analysis of the patient genes. The human
LPL gene has a span of 30 kb and comprises 10 exons that code
for a 475-amino acid protein including a 27-amino acid signal
peptide. Major rearrangements ofthe LPL gene locus were first
reported in a population of Caucasian patients (13, 14), and
recently several point mutations were also identified in Ameri-
can patients ( 15-20).
In this study, we define the molecular abnormalities in the
LPL gene of five Japanese patients with no familial relations.
Surprisingly, all five patients were found to be homozygous for
the separate gene mutations, suggesting that the genetic defects
responsible for LPL deficiency are quite heterogeneous at the
molecular level. Furthermore, expression studies ofthe mutant
proteins and measurement of the LPL mass in the patient's
plasma afforded a better understanding of the effect of these
mutations on the enzyme molecule.
Methods
Subjects. We studied five patients and their family members from inde-
pendent kindreds. A family history of consanguinity was found for
each kindred. These patients were diagnosed as LPL deficient by the
markedly reduced level of postheparin plasma LPL activity. LPL defi-
ciency was recognized in three of the five patients in infancy, and had
been overlooked in the other two until adulthood. One patient (patient
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1) was diagnosed at the age of 34 yr when he had an attack of acute
pancreatitis, and the other patient (patient 4) was asymptomatic but
was diagnosed by chance at the age of 42 during examinations for
hypertriglyceridemia. The biochemical and physical characteristics of
the subjects are shown in Table I.
Southern blot analysis and haplotyping analysis. DNAs from the
patients and normal subjects were isolated from peripheral white blood
cells. Southern blot hybridization analysis was performed after com-
plete digestion of 10 Atg of each DNA with one of the restriction en-
zymes, Hind III, Pst I, Pvu II, Nco I, or Bam HI (Boehringer Mann-
heim Biochemicals, Indianapolis, IN) as previously described (21). The
1.58-kb fragment ofhuman LPL cDNA (22) (region 1- 1,58 1) was used
as a probe for hybridization. DNA haplotypes were constructed for the
five patients using a combination of the restriction fragment length
polymorphisms (RFLPs) which were identified by Hind III, Bam HI,
and Pvu 11 (23, 24).
Genomic cloning and gene amplification by the polymerase chain
reaction. Construction ofgenomic libraries was carried out with DNAs
obtained from one patient (patient 1) and a normal subject as previ-
ously reported (21). By screening the libraries, four LPL gene fragments
that cover exons 3-9 were obtained from each library. To obtain gene
fragments containing exon 1, exon 2, and a portion ofexon 10, and to
examine the DNA sequences ofthe LPL gene from the remaining four
patients, gene amplification was performed by the polymerase chain
reaction (PCR) (25). 1 gg ofeach DNA was added to a I00-Ml reaction
mixture of 50mM KC1, 10mM Tris (pH 8.3), 1.5 mM MgCl2, 0.01%
gelatin with 0.1 nmol ofeach primer, 20 nmol ofeach dNTPs, and 2.5
U of Taq DNA polymerase (Perkin-Elmer Corp., Pomona, CA). The
reaction mixture was applied to 30 cycles of PCR (94°C 1 min; 50-
55°C 2 min; 72°C 3 min), which was preceded by an additional dena-
turation (94°C S min) and followed by an extension (72°C 7 min).
Table II shows the sequences of the oligonucleotide primers used for
PCR amplification. The sequences of the four primers, which are
marked with an asterisk, were derived from the published sequence of
the human LPL gene (12). These sets ofprimers could properly amplify
each ofthe 10 exons and the adjacent intron sequences of 10-55 bases,
except for the latter portion of exon 10 which conforms to the entire
3'-untranslated region (10). Oligonucleotide primers were synthesized
by the phosphoramidite method with a model 381A DNA synthesizer
(Applied Biosystems, Inc., Foster City, CA).
DNA sequencing. Direct sequencing of amplified DNA was per-
formed utilizing an unequal ratio of primers for the second PCR (26).
Following the first PCR, one-hundredth of the reaction mixture was
PCR amplified again as described above, together with an unequal
ratio (100: 1) ofthe same primers used in the first reaction. The single-
stranded DNA from the second PCR was used for sequencing by the
dideoxy method (27) with Sequenase (United States Biochemical
Corp., Cleveland, OH) after chloroform-extraction and filtration with a
Centricon 100 microconcentrator (Amicon Corp., Danvers, MA). The
cloned gene fragments and the PCR-amplified fragments containing
regions with strong secondary structures were sequenced after subclon-
ing into the M 13 vector mpl 8 or mpl9. All sequences were determined
on both strands and the regions across a mutation were sequenced on
the six independently amplified DNAs.
RFLP-creating PCR. To detect the mutant allele containing the
splicing mutation, an artificial RFLP was created by introducing a
Table I. Characteristics ofthe Study Subjects
Clinical manifestations
Total Apolipoprotein LPL Eruptive Lipemia
Subject* Age/sext Triglycerides Cholesterol C-Il activity xanthoma retinalis Pancreatitis Hepatosplenomegaly
mg/dl mg/dl mg/dl Amol FFA/ml/h
P 1 34/M 4,928 568 9.8 0.8 (-) (+) (+) (-)
F I 69/M 112 204 3.7 5.4
S 1-1 38/F 675 200 6.3 1.2
S 1-2 32/M 89 203 4.6 6.2
C 1-1 5/M 102 185 ND ND
C 1-2 3/M 167 170 ND ND
P 2 3m/F 19,120 824 11.2 0.9 (+) ND (-) (+)
F 2 30/M 257 150 4.6 6.7
M 2 27/F 153 108 3.3 2.4
S 2 3/F 240 133 4.6 5.7
P 3 6m/F 6,010 632 14.8 1.0 (+) (+) (-) (+)
F 3 29/M 127 157 2.9 6.9
M 3 26/F 125 158 2.0 2.7
P 4 44/F 1,528 191 6.5 1.2 (-) (-) (-) (-)
F 4 74/M 130 142 ND 5.0
M 4 71/F 173 230 ND 4.8
C 4-1 16/F 137 179 ND ND
C4-2 14/M 187 154 ND ND
P 5 23d/F 4,794 560 6.7 1.1 (+) (+) (-) (+)
F 5 31/M 53 106 3.8 6.7
M 5 28/F 106 175 3.6 3.6
S 5 3/M 67 135 4.5 3.7
Normalll 40-150 130-220 3.7±1.3' 6.4±2.1'
* P, F, M, S, and C denote patient, father, mother, sibling, and child,
for adult subjects. ' Normal values (mean±SD).
respectively. * m = months, d = days. § FFA, free fatty acid. 11 Normal values
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Table II. Oligonucleotide Primers Usedfor Amplification ofthe Exons ofthe LPL Gene
Amplified
Exon Sequence 5-Intron exon 3-Intron Total size
bp bp
1 5'-CAAGTGACAAACAGGATTCGTC-3' * 391 273 45 709
5'-ACGCCCGGGTCTGCAGGTGG-3'
2 5'-CTCCAGTTAACCTCATATCCA-3' * 36 161 32 229
5'-CAATCCACTCTTCCCCAAAGAG-3' *
3 5'-GGTGGGTATTTTAAGAAAGCT-3' 38 180 43 261
5'-AAAACACTGTTTGGACACATA-3'
4 5'-TTGGCAGAACTGTAAGCACCT-3' 43 112 46 201
5'-AGTCTTTTCACCTCTTATGATA-3'
5 5'-ATGCGAATGTCATACGAATGG-3' 61 234 35 330
5'-GAGTCACATTTAATTCGCTTC-3'
6 5'-TCTGCCGAGATACAATCTTGG-3' 39 243 38 320
5'-CTCCTTGGTTTCCTTATTrAC-3'
7 5'-CTGAATTGCCTGACTATTTGG-3' 76 121 40 237
5'-GGGACTGGTGCCATGATGAC-3'
8 5'-GCTGTCTCTATAACTAACCCA-3' 43 183 67 293
5'-ATACGGCCCCTAGGTCCTGA-3'
9 5'-TGTTCTACATGGCATATTCAC-3' 39 105 37 181
5'-TCAGGATGCCCAGTCAGCTT-3'
10$ 5'-GAAGATAATAAATTGCCCTTT-3' * 40 380 420
5'-GAATTCCAATTAAAATAGGAG-3'
* Sequences derived from the published data (12). t Exon 10 encodes the entire 3'-untranslated region of 1.95 kb.
single base mismatch into the 3' portion of an oligonucleotide PCR
primer. A Taq I cutting site was generated specifically in the mutant
allele, using the upstream primer whose DNA sequence corresponds to
the 3' end of exon 2 (5'-TGGTGATCCATGGCTGGTCG-3'; the mis-
matched nucleotide is in italic type) and the downstream primer corre-
sponding to +98 - + 117 of intron 2 (5'-GTAAGAGATCCACGTGA-
GAT-3'). The sequence of the PCR product derived from the mutant
allele was thus modified to contain a new restriction site for Taq I
(TCGA) across the exon 2-intron 2 boundary.
Allele-specific oligonucleotide hybridization. One-tenth of the PCR
products (10 ,ul) covering exon 3 were spotted in duplicate on nylon
membrane (Hybond-N, Amersham Corp., Arlington Heights, IL). The
DNA blots were hybridized with 32P end-labeled synthetic oligonucleo-
tide probes (normal, 5'-GGAATGTATGAGAGTTG-3'; mutant, 5'-
GGAATGTAAGAGAGTTG-3'). Both membranes were washed at
51°C for 15 min in 6x SSC-0.1% SDS (lX SSC = 150 mM NaCl, 15
mM sodium citrate, pH 7.0).
Site-directed mutagenesis and in vitro expression studies. To con-
struct the normal expression plasmid (pCMV-LPL), human LPL
cDNA was placed under the control ofthe CMV promoter. A 1,58 1-bp
cDNA fragment (22) encompassing the entire coding sequence was
cloned in the sense orientation into the Eco RI site ofthe Bluescript II
KS+ vector (Stratagene, La Jolla, CA). The insert was reexcised with
Hind III and Xba I, and transferred to the Hind III/Xba I sites of the
Rc/CMV vector (Invitrogen, San Diego, CA). To construct the mutant
expression plasmids, DNA segments containing each of the two mis-
sense mutations were generated by PCR and introduced into pCMV-
LPLby replacing the corresponding normal segments. Forthe construc-
tion of the mutant plasmid pLPL-His243, the 273-bp DNA fragment
(983-1,255) (8) was amplified with the mismatched 5'-primer contain-
ing the Arg -- His mutation at nucleotide 983 and was introduced into
the Eco 47III/Stu I sites of the partially digested pCMV-LPL plasmid.
To construct the pLPL-Glu204, the 21 1-bp DNA fragment (783-993)
comprising the Asp -- Glu mutation at nucleotide 867 was created by
the recombinant PCR method ofHiguchi et al. (28), which utilizes two
overlapping inside primers containing the same mutation in addition
to the outside primers. After digestion with Acc I and Eco 47III, the
resulting restricted fragment (792-982) was cloned into the partially
digested pCMV-LPL. The integrity of the normal and mutant expres-
sion plasmids was verified by DNA sequencing before transfection into
COS- I cells. DNA transfections were carried out using lipofection with
TransfectACE (Bethesda Research Laboratories, Gaithersburg, MD).
30 h after each DNA transfection, the medium was supplemented with
5 U/ml of heparin. After an additional 18 h, the culture medium and
cell extract were collected from 35-mm dishes, flash frozen, and stored
at -700C.
Lipoprotein lipase activity and mass. LPL activity in plasma and
culture media was determined as described previously (29), using glyc-
erol tri [1-'4C] oleate as substrate and selective blocking of the hepatic
lipase activity with an antiserum to human hepatic lipase. After an
overnight fast, a bolus injection of heparin (10 U/kg) was administered
to each subject, and blood was collected 10 min after heparin injection.
LPL enzyme mass was measured by a sandwich enzyme-linked im-
munosorbent assay (ELISA) recently developed in our laboratory (Ka-
wamura, M., et al., unpublished data). The ELISA utilizes two separate
polyclonal antibodies raised against a synthetic peptide of 16 amino
acids corresponding to the NH2-terminus of the mature human LPL
and against a recombinant whole human LPL. Purified human LPL
was used as the standard to calculate enzyme mass. In the expression
studies, the determination ofLPL mass and activity were performed in
octuplicates and triplicates, respectively.
Results
As shown in Table I, all five patients presented the characteris-
tically severe hypertriglyceridemia and a reduced level ofLPL
activity. The possibility of the congenital absence of apolipo-
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protein C-I1 (30), a cofactor ofLPL, could be excluded because
of the increased concentration ofapolipoprotein C-II observed
in all five patients. One sibling (SI -1) also presented moderate
hypertriglyceridemia with a markedly reduced LPL activity.
Among the other family members, C1-2, F2, and S2 exhibited
mild hypertriglyceridemia, as has been observed in other fami-
lies of LPL-deficient patients (15, 31). Their fasting serum tri-
glyceride concentrations were nearly two- to fourfold the aver-
age values oftheir respective age groups. In agreement with our
previous results with Eco RI (21), Southern blot analysis with
five other restriction enzymes showed no evidence of major
rearrangement in the LPL gene locus of the patients (data not
shown).
Nucleotide sequence of the entire LPL coding region and
the exon-intron boundaries was determined for each patient.
The results identified five distinct single-base substitutions and
confirmed that no other nucleotide alterations are present in
the LPL gene ofthe patients, except a sequence polymorphism
existing 20 bases downstream from exon 3-intron 3 junction.
The A-C transversion was also found among the normal popu-
lation. As expected from the family history of consanguinity,
all five patients were found to be homozygous for each point
mutation. Fig. 1 demonstrates the pairs of sequencing ladders
that represent sequences from both normal and patient DNA
containing the region near the respective mutations. Patient 1
has a G-to-A change at the first nucleotide of intron 2. This
single base change disrupts the invariant GT profile of the eu-
karyotic 5'-donor splice site (32). Patient 2 has a T-to-A substi-
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tution of Tyr6" (TAT), which creates a stop codon (TAA) in
exon 3 and would cause a premature termination in LPL syn-
thesis. Another nonsense mutation was identified in the gene of
patient 3 who has an A substituting for a G at Trp382 (TGG),
which also creates a premature termination codon (TGA) in
exon 8. Two missense mutations were found in the gene ofthe
remaining two patients. Patient 4 has a C-to-G transversion
that replaces Asp2" (GAC) with Glu (GAG) in exon 5, and
patient 5 has a G-to-A transition that changes Arg243 (CGC) to
His (CAC) in exon 6. To exclude the possibility ofmisincorpor-
ations during PCR (25), direct sequencing was performed for
each patient's DNA derived from six independent amplifica-
tions by separate PCRs.
Of the five point mutations described above, three can af-
fect the restriction sites recognized by the commercially avail-
able restriction enzymes. The point mutations in patients 3, 4,
and 5 were predicted to disrupt a Mbo II site, a Hinc II site, and
an Eco 47111 site, respectively. Thus in these three patients,
digestion ofthe amplified DNA with an appropriate restriction
enzyme was expected to generate a distinctive fragment which
is different in size from the normal ones (Fig. 2). Mbo II diges-
tion of the PCR-amplified products of 293 bp generated four
fragments of 143, 60, 57, and 33 bp for normal subjects. In-
stead, similar digestion of the amplified DNA from patient 3
resulted in the occurrence of the unique 203-bp fragment in
addition to the common 57- and 33-bp fragments, due to the
loss of one of the three internal Mbo II sites (Fig. 2, A and D).
Digestion of the PCR-amplified DNA containing exon 6 with
A C G T
.ri7
-
Ser'
LI!L NORMAL
PATIENT S
Figure 1. Comparison ofDNA sequences from a normal subject and the five patients. All sequences were determined on both strands by direct
sequencing of the amplified DNA, and the regions across a mutation were sequenced on the separately amplified DNAs. The sequences ofthe
sense strand (patients 1, 3, 4) or antisense strand (patients 2, 5) are shown for comparison. The bases substituted in the patients are enclosed by
the box.
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Figure 2. Detection of the three
mutations by digestion with re-
striction enzymes. Schematic
representations of the portion of
the LPL gene that were ampli-
fied by the individual PCR are
shown in panels A-C. The pairs
ofprimers used are indicated by
the arrows and the positions of
normal restriction sites by the
vertical lines. The restriction
sites disrupted by the mutations
are marked with an arrowhead.
Numbers indicate the size of the
fragments generated by the re-
spective digestions. Electropho-
retic analyses of the amplified
DNAs from the patients (P), fa-
thers (F), mothers (M), and a
normal control (C) were per-
formed with 2% agarose gel after
digestion ofthe DNAs with an
appropriate restriction enzyme.
As shown in panels D-F, the re-
spective unique fragments were
demonstrated in the DNAs from
the patients, and heterozygous
restriction patterns were con-
firmed for the parents.
Eco 47111 divides the 320-bp products into two fragments of
248 and 72 bp in normal subjects, but a similar digestion did
not cleave the amplified DNA from patient 5. This indicates
the disruption of the Eco 47 III restriction site by the missense
mutation (Fig. 2, B and E). The fact that patients 3 and 5 did
not show any normal size fragment while their parents have
both the normal and abnormal size fragments confirmed that
they are true homozygotes with the corresponding mutations
on both alleles, each of which was inherited from the paternal
and maternal pedigree. Hinc II digestion also confirmed homo-
zygosity of patient 4 for the mutation, although the DNA sam-
ples from the parents were unavailable (Fig. 2, C and F).
A
Normal Gene
5'-TGGTGATCCATGGCTGG CG-3'
ACCACTAGGTACCGACCTGC cattcoc
30 cyclos
PCR amplification
Because the remaining two mutations cause no change in a
restriction site, we developed alternative methods to detect
each mutation. The donor splice site mutation was detected by
an artificially created Taq I-RFLP which was specifically intro-
duced into the mutant allele (Fig. 3). The result confirmed the
homozygosity ofpatient 1 (P1) and demonstrated that his elder
sister (S1-1) who had moderate hypertriglyceridemia with a
markedly reduced LPL activity is also a true homozygote for
the same splicing mutation. To detect the mutant allele with
the nonsense mutation at Tyr6", allele-specific oligonucleotide
hybridization was carried out (Fig. 4). The result established
the homozygosity ofpatient 2 (P2) and also demonstrated that,
TGG TCGg taaggg
ACC AGCc at t cooc
Mutant Gene
5'-TGGTGATCCATGGCTGGTCG-3'
ACCACTAGGTACCGACCTGC tattccc
B
A137Normal I 119
Patient -o--- ---
Taq I
TGG TCGa taaggg
ACC AGCt att coc
Taq I
site
(bp) N P1 Sl-lSl-2
137 -
119 -
Figure 3. Detection of the splicing mutation by RFLP-
creating PCR. (A) The strategy for the specific introduc-
tion of an artificial Taq I site into the splicing mutant al-
lele by the RFLP-creating PCR. (B) Taq I-digestion of
the amplified DNA from the mutant allele generates the
specific 1 19-bp fragment, as depicted in the right panel.
N, P1, S 1-1, and S 1-2 denote the normal, patient 1, sister,
and brother, respectively.
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exon 2 intron 2
Normal probe: 5'- GGAATGTATGAGAGTTG -3'
Mutant probe: 5'- GGAATGTAAGAGAG1TG -3'
P2 F2 M2 S2 Pc N
Normal
Mutant II* * *
Figure 4. Detection of the nonsense mutation at Tyr6' by allele-spe-
cific oligonucleotide hybridization. The amplified genomic DNAs
containing exon 3 were dot-blotted in duplicates and hybridized with
two allele-specific probes for the normal and mutant sequences en-
compassing the nonsense mutation at Tyr6'. P2, F2, M2, S2, Pc, and
N denote the patient 2, father 2, mother 2, sister 2, compound het-
erozygote and normal control, respectively.
in addition to both parents (F2, M2), her elder sister (S2) as well
as another LPL-deficient patient (Pc) is also heterozygous for
the same mutation. Because both C1-2 and F2 are obligate
heterozygotes, all the three family members who exhibited
mild hypertriglyceridemia (C1-2, F2, and S2) are carriers for
the mutations at the LPL gene locus.
To investigate the prevalence of the point mutations de-
scribed above, we examined three additional unrelated patients
who had no family history of consanguinity. As shown above,
one patient (Pc) was a possible compound heterozygote with
only one allele containing the same mutation as patient 2. The
other two patients, however, had none ofthe mutations identi-
fied thus far.
We also constructed the DNA haplotypes for the five pa-
tients using a combination of the alleles which were deter-
mined by the three RFLPs (23, 24) (Table III). Only three ha-
plotypes were found among the patients, because haplotype C
(H2 B1 P2) was common to the three affected chromosomes
with respective mutant alleles. In 50 unrelated Japanese con-
trols, allelic frequencies were H 1 = 0.28, H2 = 0.72; B I = 0.85,
B2 = 0.15; P1 = 0.22, P2 = 0.78, respectively. Therefore, ha-
plotype C is quite likely to be the most prevailing haplotype in
the Japanese population.
The LPL enzyme mass in the postheparin plasma of the
patients was measured by an ELISA using polyclonal antibod-
ies raised against human LPL (Table IV). Virtually no LPL
enzyme mass was detected in plasma from patients 1 and 2,
suggesting that the genetic defects in these two patients are
null-allelic mutations. Regarding the other three patients,
variously decreased but significant levels of LPL mass were
found in their postheparin plasma. In contrast, the enzyme
mass in the preheparin plasma from the three patients was
uniformly at undetectable levels (data not shown).
To examine the functional significance ofthe two missense
mutations, expression plasmids coding for the normal LPL
(pCMV-LPL) as well as the Glu2o and His243 mutants (pLPL-
Glu2' and pLPL-His243) were transfected into COS-l cells, and
both the media and the cell homogenates were assayed for LPL
mass and activity. Media harvested from cells transfected with
the pLPL-Glu20" and pLPL-His243 mutant plasmids contained
decreased levels of LPL mass (26 and 24% of the level in nor-
mal control, respectively), whereas such decreases in the level
of LPL mass were less significant in the cell homogenates (73
and 61% of normal control, respectively) (Fig. 5 A). Neither of
the mutant proteins showed detectable enzymatic activity both
in the media and in the cells (Fig. 5 B). These data demon-
strated that the Asp2' -- Glu and the Arg243 -- His mutations
both result in the production ofLPL molecules which are cata-
lytically defective and are less efficiently secreted from the ex-
pressing cells.
Discussion
In this paper, we described five distinct point mutations respon-
sible for LPL deficiency and developed diagnostic tests for the
rapid detection of each mutation. We also measured the LPL
enzyme mass and performed transient expression of the mu-
tant LPL cDNAs in mammalian cells. The results provide a
new insight into the molecular basis ofLPL deficiency as well
as into the structure-function relationship of this important
enzyme.
At the first nucleotide of intron 2, patient 1 has a G-to-A
substitution that converts the invariant dinucleotides GT into
AT in the donor splice site of eukaryotes (32). It is well estab-
lished that the GT dinucleotides are essential and obligatory for
normal splicing of pre-mRNA as they are involved in the
correct splice site selection (33). In fact, we have recently dem-
onstrated aberrant splicing in this patient, which resulted in
decreased levels of LPL mRNA (Gotoda, T., et al., unpub-
lished results).
LPL is a unique enzyme with multiple functional domains
which are postulated to be confined to specific exons. Many
investigators assign the asparagine-linked glycosylation site re-
quired for the expression of enzyme activity to exon 2, the
Table III. DNA Haplotypes at the LPL Gene Locus in the Five Patients
Patient No. Mutation Haplotype Hind III Bam HI Pvu II
Patient 1 GT -> AT Haplotype A H2* Bi P1
Patient 2 Tyr6' -- Stop Haplotype B HI BI P1
Patient 3 Trp382 -* Stop Haplotype C H2 BI P2
Patient 4 Asp2'4 -* Glu Haplotype C H2 Bi P2
Patient 5 Arg243 -- His Haplotype C H2 BI P2
* HI indicates the allele characterized by the band of 17.5 kb. H2, 8.7 kb; B1, 33 kb; B2, 19 kb; P1, 7.9 kb; P2, 5.1 and 2.8 kb, respectively.
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Table IV. LPL Enzyme Mass in the Postheparin Plasma ofthe
Five Patients
Patient No. Mutation LPL enzyme mass* Protein class$
ng/ml
Patient 1 GT AT 2 Class I defect
Patient 2 Tyr6' Stop 0 Class I defect
Patient 3 Trp3"2 Stop 22 Class II or III defect
Patient 4 Asp204' Glu 118 Class II defect
Patient 5 Arg243 His 84 Class II defect
* Controls (n = 6): 410±96 (mean±SD). * Classification of protein
defects according to Auwerx et al. (7).
catalytic serine and the lipid binding domain to exon 4, the
highly conserved central domain to exon 5, and the heparin
binding site to exon 6 (8, 10, 12, 34). The introduction of a
premature stop codon into exon 3 in patient 2 can thus be
easily predicted as exerting the lethal effect on translation. Actu-
ally, LPL immunoreactive mass was completely absent in the
postheparin plasma of patient 2, as well as in that of patient 1
(Table IV). Thus, these patients exhibit the class I protein de-
fect described by Auwerx et al. (7) which is characterized by
null-phenotypic expression.
More informative is the nonsense mutation in patient 3,
which occurs in the middle of exon 8 and would terminate
translation after synthesizing > 85% of the normal LPL, in-
cluding all functional domains noted above. Earlier studies
demonstrated that chymotryptic digestion ofbovine LPL elimi-
nates the carboxy-terminal portion and causes a loss ofactivity,
not with soluble substrates but with insoluble substrates (35).
Recent peptide sequencing analysis of bovine LPL located the
chymotrypsin nick immediately after Phe39 (the equivalent of
Phe388 in human LPL) and suggested the succeeding hydropho-
bic region for another interfacial lipid binding domain (36).
A
(ng/ml)
LPL Mass
B
(nmoles FFA
/ml/min)
Our finding of a nonsense mutation at Trp382 in an LPLdefi-
cient patient supports the notion that the carboxy-terminus of
LPL is highly important, probably because it is involved in
lipid binding. Decreased levels ofmRNA, as are often observed
in nonsense mutations (37), may also contribute to the LPL
deficiency in patients 2 and 3.
Of the 448 amino acid residues consisting of human LPL,
only 30 amino acids are completely conserved both among
species and among the lipase gene family which is composed of
LPL, hepatic lipase, pancreatic lipase, and yolk protein (1 1).
The two missense mutations found in patients 4 and 5 both
occurred in one of such highly conserved amino acid residues,
suggesting an essential role of these amino acids in normal
lipolytic function.
The Asp204 -* Glu substitution in exon 5 of patient 4 is
indeed a subtle change with a single methylene addition, but
conformation analysis by the Chou and Fasman algorithm (38)
predicted that the amino acid change would disrupt a p3-sheet
configuration. Furthermore, the base change is not a common
polymorphism, because the same base change was not ob-
served in the other 50 alleles examined. Exon 5 encodes the
central homologous region which has highly conserved se-
quences (10). Recently, three missense mutations were identi-
fied in exon 5, and the validity ofeach mutation was confirmed
by in vitro expression studies. The GlyI88 Glu (15) and
Ala'76'- Thr (16) substitutions both resulted in the synthesis of
a catalytically inactive enzyme with a decreased affinity for
heparin, and the IIe'94 -- Thr change (19) produced an inactive
enzyme with normal heparin affinity. These mutant proteins
were present abundantly in the postheparin plasma and were
normally expressed in the culture medium of the transfected
cells. By contrast, COS-1 cells transfected with the mutant plas-
mid pLPL-Glu204 produced a unique inactive enzyme, which
was decreased in amount and was less efficiently secreted from
the cells (Fig. 5). In addition, the significant increment in the
LPL mass in the patient's postheparin plasma, which is charac-
LPL Activity
* Media
M Cells
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o C) Cl
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-
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Figure 5. LPL expression in COS- I
cells transfected with the normal
and mutant expression vectors. COS
cells were transfected with Rc/CMV
vector without insert (denoted
pCMV), or with pCMV-LPL carry-
ing the normal LPL cDNA, or with
pLPL-Glu4 carrying the Asp2o'
Glu mutant cDNA, or with pLPL-
His243 carrying the Arg243 -- His
mutant cDNA. (A) LPL mass is in
nanograms per milliliter. (B) LPL
activity is expressed as nanomoles
of free fatty acids per milliliter per
minute. LPL mass and activity were
measured both in the culture me-
dium (solid bars) and in cell ho-
mogenates (hatched bars).
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teristic ofthe class II defect (7), indicated normal heparin bind-
ing ofthe mutant LPL (Table IV). These effects ofthe mutation
at Asp2Os have more similarities to those of the mutations at
Arg243 in exon 6 (Fig. 5) and at Gly'42 in exon 4 (20) rather than
to those of the other mutations in exon 5. Therefore, although
the dispersion ofthe mutations in exon 5 (Ala'76, Gly'88, IIe'` ,
Asp2t4) implies the presence of an extensive region necessary
for normal LPL function, the amino acid substitutions that
occur within the same region can cause different effects on the
enzyme. It is also noteworthy that both the rather conservative
amino acid changes at Asp20" as well as at Seri" (18) can abol-
ish LPL function completely. The fact should indicate the ex-
treme intolerance of the LPL molecule to the alterations
caused by an amino acid substitution.
The G-to-A transition in exon 6 of patient 5, which was
similarly proved not to be a common polymorphism, also oc-
curs in the highly conserved Arge4. Interestingly, the same base
substitution was recently also found in a Caucasian patient
( 19). Recently, x-ray crystallographic analysis ofhuman pancre-
atic lipase revealed that the lipolytic site of the enzyme is
formed by a triad structure which is composed ofSer'52, Asp'76,
and His263 (equivalent to Ser'32, Asp'56, and His24' in human
LPL, respectively) (39). Because the Arg243 -- His substitution
occurs close to the His24' which is essential for the formation of
the catalytic triad, the change is likely to cause the disruption of
the enzyme catalytic site. Expression studies demonstrated that
the Arg243 -- His substitution not only abolishes enzyme activ-
ity but also decreases enzyme secretion.
The heterogeneity of familial LPL deficiency has been sug-
gested by biochemical (5, 6) and immunological (7) analyses.
In this study, we found heterogeneity of this disease also at the
molecular level. The diversity ofthe gene mutation was further
supported by the examinations ofthe three additional patients,
which suggested the existence of other undefined mutations
even within the relatively homogeneous Japanese population.
Taking into account such a variety of gene mutations, it is
expected that different mutations can exist on the chromo-
somes with an identical haplotype. Actually as shown in Table
III, haplotype C was found in the three affected chromosomes
with respective distinct mutations. Furthermore, haplotype C
was recently also found in the insertional mutation, and haplo-
type A in the missense mutation at Gly'88 (40). Without more
extensive RFLP analysis, DNA haplotyping can only provide
limited genetical information regarding LPL deficiency. Iden-
tification of a series of naturally occurring mutations, there-
fore, will be the first step to establish a practical diagnostic
system of familial LPL deficiency at the DNA level.
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